Randomized trial of @entity396 and cervagem in combination with a reduced dose of XXXX for induction of abortion.

@entity1 @entity390 @entity391 @entity396 @entity2918 @entity3927 @entity4999
@entity3927 (600 mg) in combination with a prostaglandin has been demonstrated to be a safe, acceptable alternative to vacuum aspiration for induction of abortion in the first 9 weeks of pregnancy. However, the efficacy and side-effects of different @entity2918 used in combination with @entity3927 have not been assessed in a randomized trial. In this study, 800 @entity1 seeking an abortion at gestational age < or = 63 days @entity4999 were randomized to receive either 0.5 mg gemeprost by vaginal pessary (group I) or 600 micrograms @entity396 (group II) by mouth approximately 48 h after taking 200 mg @entity3927 by mouth. The side-effects and number of complete abortions were used as measures of efficacy. There was no significant difference in the rate of complete abortion between group I [96.7%; 95% confidence interval (CI) 94.9-98.5%, n = 391] and group II (94.6%; 95% CI 92.3-96.9, n = 386). It was not possible to assess the outcome with certainty in the remaining 23 @entity1 . However, there were significantly more ongoing pregnancies in the @entity1 who received @entity396 than in those who received gemeprost (nine versus one, P < 0.01) and in eight of these 10 @entity1 the gestation was > 49 days. Fewer @entity1 in group II required analgesia than in group I (48 versus 60%, P < 0.001) although the number requesting opiate was similar in each group (6.9 versus 5.2%, P > 0.4). The incidence of @entity390 and @entity391 after @entity396 (47.8 and 21.9% respectively) was higher (P < 0.001) than after gemeprost (33.9 and 12% respectively).(ABSTRACT TRUNCATED AT 250 WORDS)
